UAE A roundup of the latest pharma news from the United Arab Emirates (UAE) including Julpher’s pursuit of its growth strategy with a new CEO, Global Pharma’s tech transfer deal with Egypt’s Nerhado and Pharma Solutions’ procurement of its first thalassemia generic. AstraZeneca announces move to Dubai Science Park with…
Thailand The top ten companies in the USD 6.9 billion Thai pharma market for 2021 ranked by market share, compiled by Thai banking firm Krungsti. Three of the featured firms – Mega Lifesciences, Better Pharma, and Berlin Pharma – are locals, while multinationals of the likes of AstraZeneca, Pfizer, and Novartis…
Egypt Three country managers with a recent experience of bringing new products from their company’s global portfolio into Egypt – and with big plans for more launches in coming years – outline how the product launch process has improved and why government stakeholders are more receptive than ever to industry innovations.…
USA After Big Pharma lobby groups suffered a major drug pricing blow earlier this year with the passage of the US Inflation Reduction Act (IRA), pharma industry heavyweight AbbVie is withdrawing its membership to leading industry trade groups PhRMA and BIO. AbbVie Bows Out AbbVie is leaving both of the…
Global After an almost 20-year career in Big Pharma culminating in a role as president of AstraZeneca UK, Lisa Anson took the leap into the biotech world to lead what at the time was an ailing business, UK-based Redx Pharma. Having transformed Redx into the thriving biotech that it is today,…
Global The Access to Medicine Index, a biennial report that gauges the efforts of the world’s largest pharma companies to expand access in low- and middle-income countries (LMICs), found in this year’s edition that the 20 companies surveyed have firmly responded to access issues exposed by COVID-19. GSK remains at the…
UK Pricing and market access have become increasingly hot topics in recent years, as healthcare systems across the world attempt to balance their own financial sustainability with securing the latest medical innovations and the premium costs associated with them. Health inequity and access disparities exist between both rich and developing countries,…
Egypt Country President, Hatem Werdany, provides an overview of AstraZeneca’s 50+ year legacy in Egypt and outlines the company’s plans to launch up to 25 new products there over the next three years in areas such as respiratory disease and breast cancer, and its intention to expand local manufacturing capabilities. He…
China China healthcare and life sciences news. Top stories include the NMPA approvals of CanSino’s inhaled COVID-19 vaccine and AstraZeneca’s CKD treatment, HitGen/Unison’s anti-infectives deal and the funding secured by cell therapy biotech Neukio Biotherapeutics. Neovii & Fosun Pharma sign deal to bring transplantation medicine to China (BioSpectum Asia) Switzerland-based…
Global COVID-19 vaccines and treatments continue to make headline news and bring in huge revenues for sponsor companies, but Pharma Exec’s 2022 Top 50 Companies ranking suggests that many non-COVID products are once more driving big gains. Against the backdrop of an increasingly fraught geopolitical climate and patent landscape, the next…
Global AstraZeneca’s CEO Pascal Soriot warns that the new US legislation controlling drug prices would reduce innovators’ capacity to recover drug development investments and therefore discourage innovation, especially for drugs with smaller patient pools. In a Reuters interview last week Soriot said the law recently passed in the United States that would…
Global Sarah Pope Miksinski, executive director/CMS regulatory affairs, and Gregory Rullo, senior director regulatory affairs, at AstraZeneca discuss the need for common ground among regulators and industry when it comes to patient centricity and for strategic leadership to address differing regulatory control-strategy requirements. In today’s increasingly complex and intricate pharmaceutical landscape,…
See our Cookie Privacy Policy Here